Literature DB >> 10928955

Regulation of lymphocyte proliferation by eosinophils via chymotrypsin-like protease activity and adhesion molecule interaction.

Y Matsunaga1, M Shono, M Takahashi, Y Tsuboi, K Ogawa, T Yamada.   

Abstract

We investigated the regulatory mechanisms responsible for release of eosinophil cationic protein (ECP) from eosinophils activated by platelet-activating factor (PAF) and monitored intra-cellular pH (pHi) changes using a pH-sensitive fluorescent probe. We also explored the mechanisms by which eosinophils suppress T-lymphocyte proliferation induced by phytohaemagglutinin (PHA). In these experiments, a separated culture to investigate the ECP-mediated pathway and a coculture to identify the adhesion molecules involved in eosinophil-lymphocyte interactions were employed. Chymostatin (1x10(-6) M) inhibited ECP release by about 50% via stimulation by PAF or recombinant interleukin 5(rIL-5) plus IgG. PAF (1x10(-7) M) raised eosinophil pHi from 6.9 to 7.3 within 20 s and pretreatment of these cells with chymostatin (1x10(-6) M), but not with leupeptin or E64-d, completely prevented this increase. Calcium ionophore A23187 (1x10(-7) M) induced ECP release and raised pHi to within a range similar to that of PAF, however, chymostatin had no effect on either. Chymostatin reversed ECP-mediated suppression of PHA-induced T-lymphocyte proliferation in separated cultures, but not in cocultures. In coculture, eosinophils exhibited the same level of suppression of both CD4(+) and CD8(+) T-cell proliferation in response to PHA. Monoclonal antibodies against CD11a, CD18 and CD54, but not CD11b, restored eosinophil suppression of T-lymphocyte proliferation which was chymostatin-resistant in coculture. Eosinophils were unable to suppress the proliferative response to lymphocytes to anti-CD3 stimulation. In conclusion, chymostatin specifically inhibited both the eosinophil pHi increase and ECP release induced by PAF. Eosinophils regulate PHA-induced T-lymphocyte proliferation via the ECP-mediation associated with chymotrypsin-like protease activity. These cells also control interactions with lymphocyte between adhesion molecules, CD11a, CD18 and CD54.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928955      PMCID: PMC1572229          DOI: 10.1038/sj.bjp.0703473

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

Review 1.  Structure and function of leukocyte integrins.

Authors:  R S Larson; T A Springer
Journal:  Immunol Rev       Date:  1990-04       Impact factor: 12.988

2.  Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probes generated in situ.

Authors:  J A Thomas; R N Buchsbaum; A Zimniak; E Racker
Journal:  Biochemistry       Date:  1979-05-29       Impact factor: 3.162

3.  Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation.

Authors:  M S Diamond; D E Staunton; S D Marlin; T A Springer
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

Review 4.  Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure.

Authors:  M van Engeland; L J Nieland; F C Ramaekers; B Schutte; C P Reutelingsperger
Journal:  Cytometry       Date:  1998-01-01

5.  Inhibitors of chymotrypsin-like proteases inhibit eosinophil peroxidase release from activated human eosinophils.

Authors:  Y Matsunaga; H Kido; K Kawaji; K Kamoshita; N Katunuma; T Ogura
Journal:  Arch Biochem Biophys       Date:  1994-07       Impact factor: 4.013

6.  Aerobic responses of mouse macrophages to phagocytosis against Escherichia coli as revealed by microphotometry.

Authors:  M Shono; M Yamada; H Yamaguchi; H Miyamoto
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1993-06       Impact factor: 1.770

7.  Eicosanoids derived from arachidonic and eicosapentaenoic acids inhibit T cell proliferative response.

Authors:  A C Shapiro; D Wu; S N Meydani
Journal:  Prostaglandins       Date:  1993-03

8.  The content of eosinophil cationic protein in eosinophil leucocytes. Study on normal controls and patients with bronchial asthma.

Authors:  R Dahl; P Venge; I Olsson
Journal:  Allergy       Date:  1978-06       Impact factor: 13.146

9.  The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus.

Authors:  D E Staunton; M L Dustin; H P Erickson; T A Springer
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

10.  Molecular events during membrane fusion. A study of exocytosis in rat peritoneal mast cells.

Authors:  D Lawson; M C Raff; B Gomperts; C Fewtrell; N B Gilula
Journal:  J Cell Biol       Date:  1977-02       Impact factor: 10.539

View more
  5 in total

1.  Conserved Amblyomma americanum tick Serpin19, an inhibitor of blood clotting factors Xa and XIa, trypsin and plasmin, has anti-haemostatic functions.

Authors:  Tae Kwon Kim; Lucas Tirloni; Zeljko Radulovic; Lauren Lewis; Mariam Bakshi; Creston Hill; Itabajara da Silva Vaz; Carlos Logullo; Carlos Termignoni; Albert Mulenga
Journal:  Int J Parasitol       Date:  2015-05-05       Impact factor: 3.981

Review 2.  Eosinophils in the pathogenesis of allergic airways disease.

Authors:  S G Trivedi; C M Lloyd
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

3.  Selective depletion of tumour suppressors Deleted in Colorectal Cancer (DCC) and neogenin by environmental and endogenous serine proteases: linking diet and cancer.

Authors:  Caroline M Forrest; Kara McNair; Maria C J Vincenten; L Gail Darlington; Trevor W Stone
Journal:  BMC Cancer       Date:  2016-10-06       Impact factor: 4.430

4.  Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study.

Authors:  Anli Yang; Zhiyong Guo; Qingqi Ren; Linwei Wu; Yi Ma; Anbin Hu; Dongping Wang; Haidan Ye; Xiaofeng Zhu; Weiqiang Ju; Xiaoshun He
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

5.  Eosinophils in fungus-associated allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.